Baricitinib

The treatment of autoimmune diseases has long faced the core challenge of excessive activation of inflammatory pathways, and the advent of baricitinib provides a new path for the precise intervention of such diseases. As a selective and reversible Janus kinase (JAK) 1/2 inhibitor, it blocks JAK-mediated cytokine signal transduction to inhibit the occurrence of inflammatory cascade reactions. Currently, it has been approved for indications such as moderate to severe active rheumatoid arthritis, systemic lupus erythematosus, and severe atopic dermatitis in adults, covering patients who have an inadequate response to or are intolerant of traditional disease-modifying antirheumatic drugs. In some regions, it is also included in the combined treatment regimen for severe patients with COVID-19 infection.

The global baricitinib market size has maintained a steady growth trend in recent years. In 2023, the market size exceeded 1.8 billion US dollars, with a compound annual growth rate maintained at around 12%. Due to the patent protection period, the current global market is still dominated by the original research product. In terms of the domestic market, 3 generic pharmaceutical companies won the bid in the provincial centralized procurement in 2023, with the price dropping by more than 70% compared with the original research product. With the gradual increase in the penetration rate of generic drugs, it is expected that the domestic market size will maintain an annual growth rate of more than 15% in the next three years.

The original research enterprise of baricitinib is Eli Lilly and Company, and the original research trade name is Olumiant®. The expiration date of its core compound patent in China is 2029. The original marketed dosage form is oral tablet, with specifications of 2mg and 4mg. It has been included in the Catalogue of Listed Drugs in China as a reference preparation, and is also included in the FDA Reference Preparation Catalogue. Up to now, the baricitinib API of more than 10 domestic enterprises has passed the CDE review and publicity and obtained A status registration numbers, and more than 20 other enterprises have submitted API registration applications. 6 domestic enterprises have obtained approval for the marketing of baricitinib generic preparations. (Data as of June 2025, please refer to the official CDE website for the latest information)

In response to the impurity research needs in the process of baricitinib generic drug development and quality control, CATO can provide a full set of impurity reference standards for this API. Most of the products are in stock, and orders for in-stock products placed before 16:00 will be shipped on the same day. All impurity reference standards comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the full-process research needs of enterprises such as registration and declaration, and quality testing.